There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anixa Biosciences (ANIX – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report) with bullish sentiments.
Anixa Biosciences (ANIX)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00. The company’s shares closed last Friday at $3.34, close to its 52-week low of $2.84.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anixa Biosciences with a $12.00 average price target.
See today’s best-performing stocks on TipRanks >>
Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $50.00. The company’s shares closed last Friday at $17.32, close to its 52-week low of $16.76.
According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $47.50 average price target, implying a 180.2% upside from current levels. In a report issued on October 4, Bank of America Securities also maintained a Buy rating on the stock with a $47.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANIX:
